Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor that selectively and potently inhibits peripheral COMT, reducing peripheral conversion of levodopa to 3-O-methyldopa and thereby increasing plasma exposure to levodopa and its central availability; a single 50 mg oral dose given once daily at bedtime produces sustained COMT inhibition that supports more stable levodopa plasma levels over 24 hours. From a drug development perspective opicapone is a small molecule COMT inhibitor with pharmacokinetic properties that include rapid oral absorption, high plasma protein binding, and extensive phase II metabolism (sulfation and glucuronidation) with elimination via both biliary-fecal and renal routes; clinically important considerations include timing relative to levodopa dosing, potential for drug interactions that alter catecholamine metabolism, and monitoring for common adverse events such as dyskinesia and constipation.
Parent: Opicapone
Parent: Opicapone
During synthesis and storage opicapone can generate related compounds and degradation products originating from incomplete reactions, oxidation, N-oxide formation, hydrolysis of labile functionalities, and residual synthetic intermediates; in a controlled manufacturing process the specification typically limits individual identified related compounds to not more than 0.2 percent w/w and unidentified or unspecified impurities to not more than 0.1 percent w/w, with total impurities commonly controlled to not exceed 1.0 percent w/w. Genotoxic or structurally alert impurities are addressed to meet ICH M7 guidance, with appropriate limits often set below 0.05 percent w/w or handled via toxicological qualification; residual solvents and elemental impurities are controlled to pharmacopeial limits. Known related substances monitored in stability and release testing include N-oxide derivatives, hydrolyzed ring-opened products, minor desfluoro or dealkylated intermediates, and trace amounts of synthetic precursors, each controlled within the above limits as part of the drug substance and drug product quality control strategy.
Opicapone is used as an adjunctive treatment to levodopa in patients with Parkinson’s disease who experience wearing-off fluctuations; by inhibiting peripheral COMT it prolongs levodopa plasma concentrations and helps reduce the duration and frequency of OFF periods.
Opicapone is administered at bedtime to coincide with once-daily dosing and to provide sustained COMT inhibition during the following day when levodopa dosing occurs; nighttime dosing also minimizes the chance of dosing errors and leverages the long duration of COMT inhibition to stabilize levodopa exposure across waking hours.
Opicapone selectively and reversibly binds to peripheral catechol-O-methyltransferase, inhibiting the methylation of levodopa to 3-O-methyldopa, which reduces peripheral levodopa clearance and increases the amount of levodopa available to cross the blood-brain barrier; the compound’s high binding affinity and slow dissociation kinetics result in prolonged COMT inhibition after a single daily dose.
Both entacapone and opicapone are peripheral COMT inhibitors used to enhance levodopa efficacy, but opicapone has a longer duration of action allowing once-daily dosing (commonly 50 mg at bedtime) whereas entacapone requires multiple daily doses administered with each levodopa/carbidopa dose; opicapone exhibits greater potency and longer-lasting COMT inhibition per dose, and the two drugs have distinct chemical structures, pharmacokinetic profiles, and dosing regimens, which influence clinical use and tolerability.
